Top Qs
Timeline
Chat
Perspective
Sitagliptin/metformin
Pharmaceutical drug From Wikipedia, the free encyclopedia
Remove ads
Sitagliptin/metformin, sold under the brand name Janumet among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[10] It may be used in those whose blood sugar is not controlled with metformin and a sulfonylurea.[10][11] It is taken by mouth.[10]
Common side effects include diarrhea, headache, and upper respiratory tract infections.[5] Serious side effects may include lactic acidosis, pancreatitis, low blood sugar, heart failure, joint pain, and allergic reactions.[5] It has not been properly studied in women who are pregnant or breastfeeding.[1] It contains sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin (a biguanide).[5]
The combination was approved for medical use in the United States in 2007.[5] In 2022, it was the 182nd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[12][13] It is available as a generic medication.[14][15]
Remove ads
Medical uses
Summarize
Perspective
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[5][6]
In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea; as triple combination therapy with a peroxisome proliferator-activated receptor (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist; and as add-on to insulin as an adjunct to diet and exercise to improve glycemic control in people when stable dosage of insulin and metformin alone do not provide adequate glycemic control."[7]
In December 2020, the U.S. Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 diabetes.[16] The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes.[16]
Remove ads
Society and culture
Brand names
As of 2018, the combination is marketed under several brand names, including Efficib,[8] Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, Velmetia, Istamet, Emsita, Sitaglyn, Sitazit-M, and Zaxoran.[17]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads